Clinical Trials for Uterine Cancer

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with unresectable locally advanced or metastatic solid tumors harboring eligible AKT/PI3K/PTEN pathway alterations receive the investigational oral selective AKT1 inhibitor TER-2013 alone. Patients with HR-positive/HER2-negative advanced breast cancer previously treated with an aromatase inhibitor may receive TER-2013 with fulvestrant.

ClinicalTrials.gov ID: NCT07109726

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable advanced or metastatic MSI-H/dMMR solid tumors, generally after progression on anti-PD-(L)1 therapy, receive oral MOMA-341 alone or with irinotecan or an unspecified immunotherapy. MOMA-341 is an investigational covalent inhibitor of WRN helicase, which MSI-H/dMMR tumors depend on for DNA maintenance.

ClinicalTrials.gov ID: NCT06974110

Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic Cancers

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with locally recurrent ovarian, fallopian tube, primary peritoneal, endometrial, cervical, or vaginal cancers confined to the abdomen/pelvis receive daily oral talazoparib, a PARP1/2 inhibitor and potent PARP trapper/radiosensitizer, starting before and during fractionated external-beam radiation. Eligible patients must have ECOG 0–1 (or adequate life expectancy), adequate organ function, and at least one non-previously-irradiated measurable lesion; prior RT to the planned field, carcinomatosis/ascites/hepatic metastases, or need for extended-field RT are excluded.

ClinicalTrials.gov ID: NCT03968406

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for Mismatch Repair Proficient (pMMR) Recurrent/Unresectable Endometrial Carcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with biopsy-proven pMMR endometrial carcinoma that is recurrent after surgery or de novo unresectable, with measurable disease confined to the pelvis/vagina and no extra-pelvic disease, ECOG 0–2, and no prior pelvic radiation. Treatment combines pembrolizumab (PD-1 inhibitor) with dose-escalated lenvatinib (multikinase inhibitor of VEGFR/FGFR/PDGFR/RET/KIT) given concurrently with hypofractionated pelvic EBRT.

ClinicalTrials.gov ID: NCT05603910

A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced solid tumors that have progressed after standard therapy or lack a standard treatment option receive a single intravenous infusion of IDOV-Immune. This engineered oncolytic vaccinia virus is designed to replicate preferentially in tumor cells, destroy them, and stimulate antitumor immunity.

ClinicalTrials.gov ID: NCT06910657

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic NSCLC, SCLC, endometrial cancer, or triple-negative breast cancer who have received or declined standard therapy, or have no standard options, receive IV LY4175408. This investigational antibody–drug conjugate targets PTK7 and delivers exatecan, a topoisomerase I inhibitor.

ClinicalTrials.gov ID: NCT07046923

A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory, locally advanced or metastatic NSCLC, triple-negative breast cancer, head and neck squamous cell carcinoma, esophageal or gastric/GEJ cancer, or cervical, endometrial, or ovarian cancer (ECOG 0–1) receive NRM-823 alone or with an immune checkpoint inhibitor. NRM-823 is an investigational T-cell engager intended to bring T cells into contact with tumor cells; its tumor-binding target has not been publicly confirmed.

ClinicalTrials.gov ID: NCT07182149

First-in-human, Open-label, Multi-site, Phase I/IIa, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT329 in Participants With Advanced Solid Tumors Known to Express CA19-9

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, advanced CA19-9–expressing solid tumors and no standard treatment option likely to benefit them receive BNT329, an investigational CA19-9–directed antibody–drug conjugate carrying a topoisomerase I inhibitor. Cohorts test different dosing schedules, one with a CA19-9–targeting antibody given before BNT329; a previously treated pancreatic cancer cohort compares two BNT329 doses.

ClinicalTrials.gov ID: NCT07186842

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with metastatic or locally advanced unresectable solid tumors, ECOG performance status 0–2, and no prior RBM39-targeted therapy receive oral ST-01156 on a 5-days-on, 2-days-off schedule. ST-01156 is an investigational small molecule designed to degrade RBM39, an RNA-splicing protein.

ClinicalTrials.gov ID: NCT07197554

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with progressing relapsed or refractory, locally advanced inoperable or metastatic CRPC, colorectal, lung, head and neck, gynecologic, triple-negative breast, or esophageal squamous cell cancer receive 177Lu-BetaBart in a single-arm dose-escalation and expansion study. This investigational lutetium-177–labeled antibody targets B7-H3 (CD276) to deliver radiation to tumors.

ClinicalTrials.gov ID: NCT07189871